Morgan Stanley Viking Therapeutics, Inc. Transaction History

Morgan Stanley

$1.36 Trillion
Q1 2025

A detailed history of Morgan Stanley transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Morgan Stanley holds 3,120,656 shares of VKTX stock, worth $87.4 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

3,120,656

Previous 2,593,615 20.32%

Holding current value

$87.4 Million

Previous $104 Million 27.79%

% of portfolio

0.01%

Previous 0.01%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$24.15 - $42.89 $12.7 Million - $22.6 Million	527,041 Added 20.32%	3,120,656 $75.4 Million
Q4 2024 Feb 14, 2025	BUY	$38.28 - $78.03 $27.5 Million - $56.1 Million	718,770 Added 38.34%	2,593,615 $104 Million
Q3 2024 May 14, 2025	BUY	$49.84 - $70.47 $46.2 Million - $65.4 Million	927,638 Added 97.93%	1,874,845 $119 Million
Q3 2024 Nov 14, 2024	BUY	$49.84 - $70.47 $46.2 Million - $65.4 Million	927,638 Added 97.93%	1,874,845 $119 Million
Q2 2024 May 14, 2025	SELL	$47.39 - $80.2 $78 Million - $132 Million	-1,646,408 Reduced 63.48%	947,207 $50.2 Million
Q2 2024 Oct 17, 2024	SELL	$47.39 - $80.2 $2.47 Million - $4.18 Million	-52,164 Reduced 5.22%	947,207 $50.2 Million
Q2 2024 Aug 14, 2024	SELL	$47.39 - $80.2 $2.47 Million - $4.18 Million	-52,164 Reduced 5.22%	947,207 $50.2 Million
Q1 2024 Oct 17, 2024	BUY	$17.4 - $94.5 $907,653 - $4.93 Million	52,164 Added 5.51%	999,371 $81.9 Million
Q1 2024 Aug 16, 2024	SELL	$17.4 - $94.5 $8.94 Million - $48.6 Million	-513,760 Reduced 33.95%	999,371 $81.9 Million
Q1 2024 May 15, 2024	SELL	$17.4 - $94.5 $8.94 Million - $48.6 Million	-513,760 Reduced 33.95%	999,371 $81.9 Million
Q4 2023 Aug 16, 2024	BUY	$9.24 - $19.64 $5.23 Million - $11.1 Million	565,924 Added 59.75%	1,513,131 $28.2 Million
Q4 2023 Feb 13, 2024	BUY	$9.24 - $19.64 $5.75 Million - $12.2 Million	622,449 Added 69.88%	1,513,131 $28.2 Million
Q3 2023 Nov 15, 2023	SELL	$10.92 - $16.0 $4.7 Million - $6.88 Million	-430,295 Reduced 32.57%	890,682 $9.86 Million
Q2 2023 Aug 14, 2023	BUY	$14.84 - $24.79 $6.56 Million - $11 Million	442,366 Added 50.35%	1,320,977 $21.4 Million
Q1 2023 May 15, 2023	BUY	$8.08 - $17.33 $2.41 Million - $5.16 Million	297,848 Added 51.29%	878,611 $14.6 Million
Q4 2022 Feb 14, 2023	BUY	$2.72 - $9.4 $493,739 - $1.71 Million	181,522 Added 45.47%	580,763 $5.46 Million
Q3 2022 Nov 14, 2022	SELL	$2.55 - $3.89 $667,913 - $1.02 Million	-261,927 Reduced 39.62%	399,241 $1.09 Million
Q2 2022 Oct 27, 2022	BUY	$2.11 - $3.15 $642,841 - $959,691	304,664 Added 85.46%	661,168 $1.91 Million
Q2 2022 Aug 15, 2022	BUY	$2.11 - $3.15 $642,841 - $959,691	304,664 Added 85.46%	661,168 $1.91 Million
Q1 2022 Oct 27, 2022	SELL	$3.0 - $4.88 $913,992 - $1.49 Million	-304,664 Reduced 46.08%	356,504 $1.07 Million
Q1 2022 May 13, 2022	BUY	$3.0 - $4.88 $395,583 - $643,481	131,861 Added 58.7%	356,504 $1.07 Million
Q4 2021 Feb 14, 2022	SELL	$4.6 - $6.72 $152,241 - $222,405	-33,096 Reduced 12.84%	224,643 $1.03 Million
Q3 2021 Nov 15, 2021	BUY	$5.58 - $7.04 $1.44 Million - $1.81 Million	257,739 New	257,739 $1.62 Million

Others Institutions Holding VKTX

# of Institutions

432

Shares Held

65.2M

Call Options Held

8.28M

Put Options Held

3.39M

View Full List

About Viking Therapeutics, Inc.

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $2.15B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

More about VKTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account